Status: Recruiting
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SIRPant Immunotherapeutics, Inc.Updated: Dec 20, 2024Locations: 3
Eligibility criteria
Adult, defined as age ≥ 18 (at screening), who are willing and able to provide i... [+16]
Must not have received prior ITI therapy [+19]